Message

Pioneering the future of reproductive medicine through extracellular vesicle (EV) technology.

At EXORPHIA, we are committed to creating new options in the field of Assisted Reproductive Technology (ART) by leveraging our research and development platform for extracellular vesicles (EVs).

As the trend toward later childbearing continues and the demand for infertility treatment increases, there is a growing need for new technological approaches to address challenges related to embryo development and embryo quality in IVF. We are developing an acellular EV-containing IVF culture media supplement designed to support the optimization of the ex vivo embryo culture environment, with the goal of contributing to improved IVF outcomes.

For our lead product candidate, we are building on findings from non-clinical studies and collaborating with ART clinics and academic institutions to evaluate its utility as a novel embryo culture technology, including its safety profile and embryo development- and embryo quality-related outcomes. This technology is intended for use in the ex vivo embryo culture process, contains no living cells, and is not administered to patients.

At EXORPHIA, we are focused on advancing scientifically grounded, quality-controlled technologies that can contribute to reproductive medicine. We will concentrate our management resources on the ART business.

June 2026
Koji Kuchishi
President & CEO
EXORPHIA Inc.